Floatz logo

Ifa

Gallbladder Cancer

The University of Texas Medical Branch, GalvestonmixturePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

30 Active assets in the Gallbladder Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Lisata Therapeutics, Inc.
Phase 2BBB
Capecitabine
Merck Sharp & Dohme LLC
Phase 3BB
Eloxatin
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Sevoflurane
Tokyo Medical and Dental University
Phase 4BB
Epirubicin
Merck Sharp & Dohme LLC
Phase 2BB

View all 50 →

Same molecule, other indications

Ifa is also rated in:

uveal melanomaDormant
BBB
Indicative ·
73 / 100
View asset →
melanomaDormant
BB
Indicative ·
71 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →